Possible Clinical Effects of Ketoconazole on Sorafenib-induced Hand–Foot Skin Reaction and Cytoprotection Mechanisms of Antifungal Agents against Multikinase Inhibitor-induced Keratinocyte Toxicity
DOI:
https://doi.org/10.2340/actadv.v105.40697Keywords:
Multikinase inhibitor, Sorafenib, Antifungal drug, Ketoconazole, ItraconazoleAbstract
In recent years, molecular target drugs have become integral in treating malignant tumours. Multikinase inhibitors (MKIs) have been associated with serious skin disorders, including hand–foot skin reaction (HFSR), which impair patient quality of life, often disrupting activities of daily living necessitating dose reduction or discontinuation. As the pathogenic mechanisms of these skin disorders are unknown, no effective treatments have been established. Previously, by drug repurposing using an in vitro culture system, certain azole antifungal drugs (AFDs) were identified that prevented sorafenib-induced cell death of normal human epidermal keratinocytes. In this study, topical ketoconazole demonstrated clinical improvement in hyperkeratosis and pain associated with sorafenib-induced HFSR. Investigation of the mechanism using the in vitro culture system revealed sorafenib to be particularly cytotoxic among MKIs. Annexin V and TUNEL staining revealed apoptosis was mainly involved in this cytotoxicity. Antibody arrays and western blot showed increased levels of secretion of interleukin-1 receptor antagonist and macrophage migration inhibitory factor in culture supernatants. AFDs suppressed the secretion of these cytokines and reduced apoptosis in keratinocytes. This study reveals one aspect of the pathogenesis of sorafenib-induced HFSR and demonstrates that AFDs may be an effective treatment.
Downloads
References
Lee YT, Tan YJ, Oon CE. Molecular targeted therapy: treating cancer with specificity. Eur J Pharmacol 2018; 834: 188–196.
https://doi.org/10.1016/j.ejphar.2018.07.034 DOI: https://doi.org/10.1016/j.ejphar.2018.07.034
Ancker OV, Krüger M, Wehland M, Infanger M, Grimm D. Multikinase inhibitor treatment in thyroid cancer. Int J Mol Sci 2019; 21: 10.
https://doi.org/10.3390/ijms21010010 DOI: https://doi.org/10.3390/ijms21010010
Balagula Y, Wu S, Su X, Feldman DR, Lacouture ME. The risk of hand foot skin reaction to pazopanib, a novel multikinase inhibitor: a systematic review of literature and meta-analysis. Invest New Drugs 2012; 30: 1773–1781.
https://doi.org/10.1007/s10637-011-9652-2 DOI: https://doi.org/10.1007/s10637-011-9652-2
Anderson R, Jatoi A, Robert C, Wood LS, Keating KN, Lacouture ME. Search for evidence-based approaches for the prevention and palliation of hand–foot skin reaction (HFSR) caused by the multikinase inhibitors (MKIs). Oncologist 2009; 14: 291-302.
https://doi.org/10.1634/theoncologist.2008-0237 DOI: https://doi.org/10.1634/theoncologist.2008-0237
Wang P, Tan G, Zhu M, Li W, Zhai B, Sun X. Hand–foot skin reaction is a beneficial indicator of sorafenib therapy for patients with hepatocellular carcinoma: a systemic review and meta-analysis. Expert Rev Gastroenterol Hepatol 2018; 12: 1–8.
https://doi.org/10.1080/17474124.2017.1373018 DOI: https://doi.org/10.1080/17474124.2017.1373018
Michaelson MD, Cohen DP, Li S, Motzer RJ, Escudier B, Barrios CH, et al. Hand–foot syndrome (HFS) as a potential biomarker of efficacy in patients (pts) with metastatic renal cell carcinoma (mRCC) treated with sunitinib (SU). J Clin Oncol 2011; 29: 320.
https://doi.org/10.1200/jco.2011.29.7_suppl.320 DOI: https://doi.org/10.1200/jco.2011.29.7_suppl.320
Lacouture ME, Reilly LM, Gerami P, Guotart J. HFSR in cancer patients treated with the MKIs sorafenib and sunitinib. Ann Oncol 2008; 19: 1955–1961.
https://doi.org/10.1093/annonc/mdn389 DOI: https://doi.org/10.1093/annonc/mdn389
Kamata Y, Kato R, Tominaga M, Toyama S, Komiya E, Utsumi J, et al. Identification of keratinocyte cytoprotectants against toxicity by the multikinase inhibitor sorafenib using drug repositioning. JID Innov 2024; 4:100271.
https://doi.org/10.1016/j.xjidi.2024.100271 DOI: https://doi.org/10.1016/j.xjidi.2024.100271
Blum JL, Jones SE, Buzdar AU, LoRusso PM, Kuter I, Vogel C, et al. Multicenter phase II study of capecitabine in paclitaxel-refractory metastatic breast cancer. J Clin Oncol 1999; 17: 485–493.
https://doi.org/10.1200/JCO.1999.17.2.485 DOI: https://doi.org/10.1200/JCO.1999.17.2.485
Tsai YC, Tsai TF. Itraconazole in the treatment of nonfungal cutaneous diseases: a review. Dermatol Ther (Heidelb) 2019; 9: 271–280.
https://doi.org/10.1007/s13555-019-0299-9 DOI: https://doi.org/10.1007/s13555-019-0299-9
Tresnanda RI, Pramod SV, Safriadi F. Ketoconazole for the treatment of docetaxel-naïve metastatic castration--resistant prostate cancer (mCRPC): a systematic review. Asian Pac J Cancer Prev 2021; 22: 3101–3107.
https://doi.org/10.31557/APJCP.2021.22.10.3101 DOI: https://doi.org/10.31557/APJCP.2021.22.10.3101
Simões Corrêa Galendi J, Correa Neto ANS, Demetres M, Boguszewski CL, Nogueira VDSN. Effectiveness of medical treatment of Cushing’s disease: a systematic review and meta-analysis. Front Endocrinol (Lausanne) 2021; 12: 732240.
https://doi.org/10.3389/fendo.2021.732240 DOI: https://doi.org/10.3389/fendo.2021.732240
Chen Y, Chen HN, Wang K, Zhang L, Huang Z, Liu J, et al. Ketoconazole exacerbates mitophagy to induce apoptosis by downregulating cyclooxygenase-2 in hepatocellular carcinoma. J Hepatol 2019; 70: 66–77.
https://doi.org/10.1016/j.jhep.2018.09.022 DOI: https://doi.org/10.1016/j.jhep.2018.09.022
Wilhelm SM, Carter C, Tang L, Wilkie D, McNabola A, Rong H, et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 2004; 64: 7099–7109.
https://doi.org/10.1158/0008-5472.CAN-04-1443 DOI: https://doi.org/10.1158/0008-5472.CAN-04-1443
Liu L, Cao Y, Chen C, Zhang X, McNabola A, Wilkie D, et al. Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5. Cancer Res 2006; 66: 11851–11858.
https://doi.org/10.1158/0008-5472.CAN-06-1377 DOI: https://doi.org/10.1158/0008-5472.CAN-06-1377
Atale N, Gupta S, Yadav UC, Rani V. Cell-death assessment by fluorescent and nonfluorescent cytosolic and nuclear staining techniques. J Microsc 2014; 255: 7–19.
https://doi.org/10.1111/jmi.12133 DOI: https://doi.org/10.1111/jmi.12133
Rieger AM, Nelson KL, Konowalchuk JD, Barreda DR. Modified annexin V/propidium iodide apoptosis assay for accurate assessment of cell death. J Vis Exp 2011; 50: 2597.
https://doi.org/10.3791/2597-v DOI: https://doi.org/10.3791/2597-v
Zadoroznyj A, Dubrez L. Cytoplasmic and nuclear functions of cIAP1. Biomolecules 2022; 12: 322.
https://doi.org/10.3390/biom12020322 DOI: https://doi.org/10.3390/biom12020322
Gill C, Dowling C, O’Neill AJ, Watson RW. Effects of cIAP-1, cIAP-2 and XIAP triple knockdown on prostate cancer cell susceptibility to apoptosis, cell survival and proliferation. Mol Cancer 2009; 8: 39.
https://doi.org/10.1186/1476-4598-8-39 DOI: https://doi.org/10.1186/1476-4598-8-39
Varfolomeev E, Goncharov T, Fedorova AV, Dynek JN, Zobel K, Deshayes K, et al. c-IAP1 and c-IAP2 are critical mediators of tumor necrosis factor alpha (TNFalpha)-induced NF-kappaB activation. J Biol Chem 2008; 283: 24295–2429.
https://doi.org/10.1074/jbc.C800128200 DOI: https://doi.org/10.1074/jbc.C800128200
Kocab AJ, Duckett CS. Inhibitor of apoptosis proteins as intracellular signaling intermediates. FEBS J 2016; 283: 221–231.
https://doi.org/10.1111/febs.13554 DOI: https://doi.org/10.1111/febs.13554
Onozaki K. Interleukin1: from cell growth control to chronic inflammatory diseases. Yakugaku Zasshi 2013; 133: 645–660.
https://doi.org/10.1248/yakushi.13-00064 DOI: https://doi.org/10.1248/yakushi.13-00064
Di Paolo NC, Shayakhmetov DM. Interleukin 1α and the inflammatory process. Nat Immunol 2016; 17: 906–913.
https://doi.org/10.1038/ni.3503 DOI: https://doi.org/10.1038/ni.3503
Alexander JK, Cox GM, Tian JB, Zha AM, Wei P, Kigerl KA, et al. Macrophage migration inhibitory factor (MIF) is essential for inflammatory and neuropathic pain and enhances pain in response to stress. Exp Neurol 2012; 236: 351–362.
https://doi.org/10.1016/j.expneurol.2012.04.018 DOI: https://doi.org/10.1016/j.expneurol.2012.04.018
Providence KM, Higgins SP, Mullen A, Battista A, Samarakoon R, Higgins CE, et al. SERPINE1 (PAI-1) is deposited into keratinocyte migration “trails” and required for optimal monolayer wound repair. Arch Dermatol Res 2008; 300: 303–310.
https://doi.org/10.1007/s00403-008-0845-2 DOI: https://doi.org/10.1007/s00403-008-0845-2
Rossignol P, Ho-Tin-Noé B, Vranckx R, Bouton MC, Meilhac O, Lijnen HR, et al. Protease nexin-1 inhibits plasminogen activation-induced apoptosis of adherent cells. J Biol Chem 2004; 279: 10346–1356.
https://doi.org/10.1074/jbc.M310964200 DOI: https://doi.org/10.1074/jbc.M310964200
Additional Files
Published
How to Cite
Issue
Section
Categories
License
Copyright (c) 2025 Rui Kato, Yayoi Kamata, Mitsutoshi Tominaga, Ryoma Kishi, Takahide Kaneko, Akira Tsujimura, Yasushi Suga, Kenji Takamori
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
All digitalized ActaDV contents is available freely online. The Society for Publication of Acta Dermato-Venereologica owns the copyright for all material published until volume 88 (2008) and as from volume 89 (2009) the journal has been published fully Open Access, meaning the authors retain copyright to their work.
Unless otherwise specified, all Open Access articles are published under CC-BY-NC licences, allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material for non-commercial purposes, provided proper attribution to the original work.
